Featured Research

from universities, journals, and other organizations

Low-dose treatment may block malaria transmission

Date:
November 14, 2013
Source:
London School of Hygiene & Tropical Medicine
Summary:
Lower doses of the antimalarial drug primaquine are as effective as higher doses in reducing malaria transmission, according to a study.

Lower doses of the antimalarial drug primaquine are as effective as higher doses in reducing malaria transmission, according to a study published today in Lancet Infectious Diseases by London School of Hygiene & Tropical Medicine researchers.

Primaquine is one of the few antimalarial drugs that targets the transmission stages of the malaria parasite, the gametocytes, and is therefore considered to be an important tool for malaria elimination.

However, standard doses of the drug cause reduced blood count in individuals with a deficiency in glucose-6-phosphate dehydrogenase (G6PD) enzyme. This red blood cell disorder is common in malaria endemic areas, and has therefore limited the use of primaquine in malaria programmes, and prompted the World Health Organization (WHO) to advise a reduction in dosage from 0.75 mg/kg to 0.25mg/kg. But until now, the efficacy of lower doses of primaquine had not been formally evaluated.

The study, carried out in Jinja, Uganda, treated G6PD-normal children with a conventional anti-malarial drug either on its own or with one of three different doses of primaquine. The subsequent carriage of malaria gametocytes was monitored for two weeks and safety outcomes were monitored for four weeks. Results showed that a dose of 0.4 mg/kg, approximately half of the previously recommended dose (0.75 mg/kg), was as effective at reducing the transmission potential of individuals with malaria.

These results establish that low dose primaquine is still effective and safe in a G6PD-normal population, and paves the way for using low-dose primaquine as a component of strategies to reduce malaria transmission and to stop the spread of drug-resistant malaria parasites.

The next step is to include the current WHO-recommended 0.25 mg/kg dose of primaquine in efficacy studies, and to test the safety of low dose primaquine in G6PD-deficient individuals.

Lead author Dr Chi Eziefula, Wellcome Trust clinical research fellow, said: "Until now, the use of primaquine was limited because of safety concerns, but lower doses had never been tested formally. These findings, that efficacy is retained at a lower dose, imply that primaquine could play an important role in malaria elimination programmes. We now need to evaluate the safety of low-dose primaquine in G6PD-deficient individuals. More questions remain to be answered regarding the best operational strategy for the deployment of primaquine to block malaria transmission."

Co-author Professor Chris Drakeley, Director of the London School of Hygiene & Tropical Medicine's Malaria Centre, said: "This work is a crucial step in the evaluation of primaquine as a malaria transmission blocking intervention. Further work is needed to show reduced infectivity to mosquitoes and to confirm the improved safety of these lower doses."

Professor Moses Kamya of the Infectious Disease Research Collaboration in Kampala, Uganda noted: "This study provides important contemporary information that allows malaria control programmes in endemic countries in Africa to consider the use of primaquine as part of their efforts to deal with this killer disease."


Story Source:

The above story is based on materials provided by London School of Hygiene & Tropical Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alice C Eziefula, Teun Bousema, Shunmay Yeung, Moses Kamya, Asiphas Owaraganise, Grace Gabagaya, John Bradley, Lynn Grignard, Kjerstin H W Lanke, Humphrey Wanzira, Arthur Mpimbaza, Samuel Nsobya, Nicholas J White, Emily L Webb, Sarah G Staedke, Chris Drakeley. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. The Lancet Infectious Diseases, 2013; DOI: 10.1016/S1473-3099(13)70268-8

Cite This Page:

London School of Hygiene & Tropical Medicine. "Low-dose treatment may block malaria transmission." ScienceDaily. ScienceDaily, 14 November 2013. <www.sciencedaily.com/releases/2013/11/131114102524.htm>.
London School of Hygiene & Tropical Medicine. (2013, November 14). Low-dose treatment may block malaria transmission. ScienceDaily. Retrieved April 19, 2014 from www.sciencedaily.com/releases/2013/11/131114102524.htm
London School of Hygiene & Tropical Medicine. "Low-dose treatment may block malaria transmission." ScienceDaily. www.sciencedaily.com/releases/2013/11/131114102524.htm (accessed April 19, 2014).

Share This



More Health & Medicine News

Saturday, April 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins